secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protalix BioTherapeutics, Inc. (PLX)
CIK:        0001006281
Form:       8-K
Filed at:   2025-11-03T23:59:59+00:00
Accession:  0001104659-25-105594
Event type: regulatory
Sentiment:  negative
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protalix and Chiesi request re-examination of negative EMA opinion on Elfabrio E4W dosing regimen
--------------------------------------------------------------------------------

- CHMP issued negative opinion on Elfabrio 2 mg/kg every-4-weeks dosing regimen; re-examination requested.
- Existing EU marketing authorization for every-2-weeks regimen remains in effect pending outcome.
- Approved E2W dosing regimen unchanged; companies committed to addressing Fabry community needs.
- Re-examination process underway; timeline for final EC decision not disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1006281/000110465925105594/0001104659-25-105594-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1006281/000110465925105594/plx-20251103x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-105594

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer